Balanced Pharma Inc. (BPI), a North Carolina-based firm, has lately introduced that France-based Septodont has made a strategic funding to assist the commercialization of its new dental injection medication.
BPI additionally mentioned that Septodont COO Atif Zia has joined its Board of Administrators.
“We’re very proud so as to add Septodont to the rising listing of dental business members investing within the improvement of those necessary merchandise and to have Atif [Zia] as a part of our management staff,” mentioned Dr. Scott Keadle, a retired dentist and CEO of Balanced Pharma.
Thus far, BPI has raised about $6.5 million of its present $8-million funding spherical. When closed, this spherical will convey complete funding within the firm to roughly $12 million, together with greater than $9 million from dentists and different dental business insiders.
The corporate’s targets embody providing multi-day ache aid to scale back opioid use following orthopedic and oral surgical procedure, in addition to growing quicker, much less painful, and extra dependable native anesthesia for dental procedures.
Flagship dental medication: BPI-001 and BPI-002
Balanced Pharma’s flagship merchandise, BPI-001 and BPI-002, are reformulated variations of the injectable anesthetics lidocaine and articaine. Each function improved salt and acid steadiness to cut back ache, pace up onset, and improve reliability.
The medication will probably be packaged in normal dental cartridges, eliminating the necessity for brand spanking new tools or scientific protocol adjustments. The corporate plans to launch BPI-001 within the U.S. by the fourth quarter of 2027, adopted by BPI-002 and enlargement into international markets. BPI estimates the 2 merchandise will compete in a U.S. retail market valued at $2.9 billion yearly.
Non-opioid analgesic BPI-004
One other product, BPI-004, is a non-opioid injectable analgesic combining tetracaine (0.2%), lidocaine (0.4%), and epinephrine (1:250,000). When administered throughout surgical procedure, BPI-004 is designed to offer as much as three days of ache aid with low toxicity, minimal motor impairment, and decreased opioid reliance.
Balanced Pharma goals to convey BPI-004 to the U.S. market by the second quarter of 2025 underneath a 503(b) exemption. The corporate expects it to compete with bupivacaine and liposomal bupivacaine within the U.S. retail market, which is valued at $9 billion yearly.
BPI’s proprietary know-how platform was developed by a dentist and helps new injectable anesthetic and analgesic medication for numerous functions, together with orthopedic, common, and oral surgical procedures, in addition to common dentistry.
Buying rights to non-opioid drug
The information comes amid the U.S. and Canadian opioid disaster. And this partly explains why BPI in November acquired the rights to Enduracaine Dental, a non-opioid injectable ache aid drug for post-surgical use in dentistry.
In any case, dentists rank among the many main prescribers of opioids, having written greater than 8.9 million opioid prescriptions in america in 2022, contributing to a heightened threat of dependency. Moreover, Canadians are the second-largest per-capita customers of prescription opioids globally, consuming greater than 34,000 every day doses (equal to 100 mg of morphine) per million individuals between 2013 and 2015. Compared, the UK reported 12,000 every day doses per million individuals, Sweden reported 10,000, and Japan just one,200.